Four-month treatment with GLP-2 significantly increases hip BMD. A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD

Bone

Volumn 45, Issue 5, 2009, Pages 833-842

  Henriksen, Dennis B ^a   Alexandersen, Peter ^b   Hartmann, Bolette ^a   Adrian, Charlotte L ^a   Byrjalsen, Inger ^c   Bone, Henry G ^d   Holst, Jens J ^e   Christiansen, Claus ^c  

^a Sanos Bioscience   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c NORDIC BIOSCIENCE A S   (Denmark)

^d Michigan Bone and Mineral Clinic   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bone turnover markers; GLP 2; Hip BMD; Osteocalcin; Serum CTX

Indexed keywords

CALCIUM; GLUCAGON LIKE PEPTIDE 2; OSTEOCALCIN; PLACEBO; SODIUM CHLORIDE; VITAMIN D;

ABDOMINAL PAIN; AGED; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD TOXICITY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CHONDROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; EYE DISEASE; FEMALE; HIP; HOT FLUSH; HUMAN; IMMUNOPATHOLOGY; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE HYPERSENSITIVITY; KIDNEY DISEASE; LIGAMENT DISEASE; LYMPHATIC SYSTEM DISEASE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OSSIFICATION; OSTEOARTHRITIS; OSTEOPENIA; PERIODONTITIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN DISEASE; SORE THROAT; TACHYPHYLAXIS; TENDON DISEASE; TREATMENT DURATION; URINARY TRACT DISEASE; URINARY TRACT INFECTION; VASCULAR DISEASE; VOMITING;

AGED; BONE DENSITY; BONE RESORPTION; CIRCADIAN RHYTHM; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMUR NECK; GLUCAGON-LIKE PEPTIDE 2; HIP; HUMANS; INJECTIONS, SUBCUTANEOUS; OSTEOGENESIS; PLACEBOS; POSTMENOPAUSE; SPINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349279885     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.07.008     Document Type: Article

References (32)

1. Karsdal M.A., Neutzsky-Wulff A.V., Dziegiel M.H., Christiansen C., and Henriksen K. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem. Biophys. Res. Commun. 366 (2008) 483-488
2. Pederson L., Ruan M., Westendorf J.J., Khosla S., and Oursler M.J. Regulation of bone for mation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 20764-20769
3. Burr D.B. Targeted and nontargeted remodeling. Bone 30 (2002) 2-4
4. Parfitt A.M. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 30 (2002) 5-7
5. Qvist P., Christgau S., Pedersen B.J., Schlemmer A., and Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31 (2002) 57-61
6. Wichers M., Schmidt E., Bidlingmaier F., and Klingmuller D. Diurnal rhythm of CrossLaps in human serum. Clin. Chem. 45 (1999) 1858-1860
7. Pietschmann P., Resch H., Woloszczuk W., and Willvonseder R. A circadian rhythm of serum osteocalcin levels in postmenopausal osteoporosis. Eur. J. Clin. Invest. 20 (1990) 310-312
8. Caillot-Augusseau A., Vico L., Heer M., Voroviev D., Souberbielle J.C., Zitterman A., et al. Space flight is associated with rapid decreases of undercarboxylated osteocalcin and increases of markers of bone resorption without changes in their circadian variation: observations in two cosmonauts. Clin. Chem. 46 (2000) 1136-1143
9. Christgau S., Bitsch-Jensen O., Bjarnason N.H., Henriksen E.G., Qvist P., Alexandersen P., et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26 (2000) 505-511
10. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., and Christiansen C. Mechanism of circadian variation in bone resorption. Bone 30 (2002) 307-313
11. Clowes J.A., Hannon R.A., Yap T.S., Hoyle N.R., Blumsohn A., and Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30 (2002) 886-890
12. Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsboll T., Hartmann B., Henriksen E.E., et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J. Bone Miner. Res. 18 (2003) 2180-2189
13. Burrin D.G., Petersen Y., Stoll B., and Sangild P. Glucagon-like peptide 2: a nutrient-responsive gut growth factor. J. Nutr. 131 (2001) 709-712
14. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122 (2002) 531-544
15. Holst J.J. Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2. Regul. Pept. 93 (2000) 45-51
16. Henriksen D.B., Alexandersen P., Byrjalsen I., Hartmann B., Bone H.G., Christiansen C., et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 34 (2004) 140-147
17. Henriksen D.B., Alexandersen P., Hartmann B., Adrian C.L., Byrjalsen I., Bone H.G., et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 40 (2007) 723-729
18. Hartmann B., Harr M.B., Jeppesen P.B., Wojdemann M., Deacon C.F., Mortensen P.B., et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J. Clin. Endocrinol. Metab. 85 (2000) 2884-2888
19. Parfitt A.M. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J. Cell. Biochem. 55 (1994) 273-286
20. Bettica P., Bevilacqua M., Vago T., Masino M., Cucinotta E., and Norbiato G. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared. J. Clin. Endocrinol. Metab. 82 (1997) 3034-3039
21. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337 (1997) 1641-1647
22. Thiebaud D., Burckhardt P., Kriegbaum H., Huss H., Mulder H., Juttmann J.R., et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am. J. Med. 103 (1997) 298-307
23. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio L.H., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J. Bone Miner. Res. 24 (2009) 153-161
24. Riggs B.L., Wahner H.W., Seeman E., Offord K.P., Dunn W.L., Mazess R.B., et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J. Clin. Invest. 70 (1982) 716-723
25. Seeman E. Structural basis of growth-related gain and age-related loss of bone strength. Rheumatology (Oxford) 47 Suppl. 4 (2008) iv2-iv8
26. Jarvinen T.L., Sievanen H., Jokihaara J., and Einhorn T.A. Revival of bone strength: the bottom line. J. Bone Miner. Res. 20 (2005) 717-720
27. Lotz J.C., Cheal E.J., and Hayes W.C. Stress distributions within the proximal femur during gait and falls: implications for osteoporotic fracture. Osteoporos. Int. 5 (1995) 252-261
28. Rockoff S.D., Sweet E., and Bleustein J. The relative contribution of trabecular and cortical bone to the strength of human lumbar vertebrae. Calcif. Tissue Res. 3 (1969) 163-175
29. Gottschalck I.B., Jeppesen P.B., Hartmann B., Holst J.J., and Henriksen D.B. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand. J. Gastroenterol. 43 (2008) 1304-1310
30. Gottschalck I.B., Jeppesen P.B., Holst J.J., and Henriksen D.B. Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scand. J. Gastroenterol. (2008) 1-9
31. Holst J.J., Hartmann B., Gottschalck I.B., Jeppesen P.B., Miholic J., and Henriksen D.B. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scand. J. Gastroenterol. 42 (2007) 814-820
32. Bjerknes M., and Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 12497-12502